Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil Transdermal Patch in Moderate to Severe Cancer Pain
CTR20231725Phase 2Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sufentanil in cancer pain, chronic pain, sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
sufentanil
03
Conditions
cancer painchronic pain
Beyond the preview
Go deeper on CTR20231725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231725.